PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025

SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 37th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Tuesday, December 2 at 8:30 a.m. Eastern Time.

GlobeNewsWire • Nov 20, 2025

Artisan Global Discovery Fund: Q3 Delivers Strong Results Amid Trimming And Exits

The portfolio generated a modestly positive absolute return in Q3, but it trailed the MSCI All Country World Small Mid Index. The Q3 underperformance was driven by stock selection in the IT, financials and consumer discretionary sectors. On the positive side, stock selection in the health care and industrials sectors was the strongest contributor to performance.

Seeking Alpha • Nov 20, 2025

PROCEPT BioRobotics Corporation (PRCT) Q3 2025 Earnings Call Transcript

PROCEPT BioRobotics Corporation ( PRCT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Matthew Bacso - Vice President of Investor Relations Larry Wood - President, CEO & Director Kevin Waters - Executive VP & CFO Conference Call Participants Matthew O'Brien - Piper Sandler & Co., Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Richard Newitter - Truist Securities, Inc., Research Division Patrick Wood - Morgan Stanley, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Christopher Pasquale - Nephron Research LLC Suraj Kalia - Oppenheimer & Co. Inc., Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Joshua Jennings - TD Cowen, Research Division Brett Gasaway - Leerink Partners LLC, Research Division Michael Sarcone - Jefferies LLC, Research Division Stephanie Piazzola - BofA Securities, Research Division Presentation Operator Good afternoon, and welcome to PROCEPT BioRobotics Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Nov 5, 2025

PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance

SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025.

GlobeNewsWire • Nov 4, 2025

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Beats Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.4 per share a year ago.

Zacks Investment Research • Nov 4, 2025

2 Robotics Stocks Riding the Sensor and Medical Boom

Robotics companies building enabling systems like sensors and LiDAR attracted $1.6 billion in 2025, as every robot needs vision capabilities. Medical robotics shows the clearest path from startup to profitability, with surgical automation growing 56% annually in emerging procedures.

The Motley Fool • Oct 29, 2025

Earnings Preview: PROCEPT BioRobotics Corporation (PRCT) Q3 Earnings Expected to Decline

PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 28, 2025

Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares?

Chicago Capital added 999,873 shares of Procept BioRobotics with an estimated purchase value of $45.65 million based on the average price for the quarter. The transaction represents a trade size equal to 1.12% of Chicago Capital's 13F reportable assets under management (AUM) for the period.

The Motley Fool • Oct 24, 2025

PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025

SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

GlobeNewsWire • Oct 15, 2025

Procept BioRobotics: A Strong Challenger Positioned To Be A Future Leader

PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding indications, and international momentum support margin expansion, scalability, and long-term growth in its niche market. Valuation is attractive at current levels, with a DCF-derived target price of $50.9 and profitability expected by the end of 2027, offering an attractive accumulation opportunity.

Seeking Alpha • Oct 6, 2025